Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Recommendation of “Buy” by Brokerages

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) have been assigned a consensus recommendation of “Buy” from the fifteen brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $37.9231.

DFTX has been the subject of a number of analyst reports. HC Wainwright raised their price target on Definium Therapeutics from $55.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Jefferies Financial Group began coverage on shares of Definium Therapeutics in a research note on Thursday, January 29th. They set a “buy” rating and a $30.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and set a $48.00 price objective (down from $49.00) on shares of Definium Therapeutics in a research note on Friday, May 8th. Robert W. Baird set a $37.00 price objective on shares of Definium Therapeutics in a research note on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Tuesday, April 21st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of DFTX. Commodore Capital LP boosted its stake in Definium Therapeutics by 10.5% during the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after buying an additional 475,000 shares during the period. Orbimed Advisors LLC purchased a new position in Definium Therapeutics during the third quarter worth $4,337,000. Rosalind Advisors Inc. boosted its stake in Definium Therapeutics by 78.6% during the third quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock worth $8,842,000 after buying an additional 330,000 shares during the period. Two Sigma Investments LP boosted its stake in Definium Therapeutics by 424.9% during the third quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock worth $3,495,000 after buying an additional 239,965 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Definium Therapeutics by 11.0% during the third quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock worth $23,732,000 after buying an additional 198,878 shares during the period. 27.91% of the stock is owned by hedge funds and other institutional investors.

Definium Therapeutics Price Performance

NASDAQ DFTX opened at $22.50 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69. The company has a market capitalization of $2.24 billion, a P/E ratio of -9.04 and a beta of 2.37. Definium Therapeutics has a one year low of $6.34 and a one year high of $26.25. The stock has a 50 day moving average price of $20.76 and a 200-day moving average price of $16.71.

Definium Therapeutics (NASDAQ:DFTX) last posted its earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). As a group, equities analysts predict that Definium Therapeutics will post -2.26 EPS for the current fiscal year.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.